PriceTargets.com logo

Bone Biologics - BBLG Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $67.50
  • Forecasted Upside: 9,275.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.72 As of 09/27/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for BBLG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bone Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBLG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBLG

Analyst Price Target is $67.50
▲ +9,275.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bone Biologics in the last 3 months. The average price target is $67.50, with a high forecast of $67.50 and a low forecast of $67.50. The average price target represents a 9,275.00% upside from the last price of $0.72.

This chart shows the closing price for BBLG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Bone Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/13/2023EF Hutton Acquisition Co. IReiterated RatingBuy$67.50
4/3/2023EF Hutton Acquisition Co. IReiterated RatingBuy$67.50
10/18/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$67.50
(Data available from 9/28/2018 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/29/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Bone Biologics logo
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $0.72
Low: $0.70
High: $0.75

50 Day Range

MA: $0.94
Low: $0.62
High: $1.45

52 Week Range

Now: $0.72
Low: $0.57
High: $35.40

Volume

24,393 shs

Average Volume

157,802 shs

Market Capitalization

$2.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Bone Biologics?

The following Wall Street sell-side analysts have issued research reports on Bone Biologics in the last year: EF Hutton Acquisition Co. I.
View the latest analyst ratings for BBLG.

What is the current price target for Bone Biologics?

1 Wall Street analysts have set twelve-month price targets for Bone Biologics in the last year. Their average twelve-month price target is $67.50, suggesting a possible upside of 9,275.0%. EF Hutton Acquisition Co. I has the highest price target set, predicting BBLG will reach $67.50 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $67.50 for Bone Biologics in the next year.
View the latest price targets for BBLG.

What is the current consensus analyst rating for Bone Biologics?

Bone Biologics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BBLG will outperform the market and that investors should add to their positions of Bone Biologics.
View the latest ratings for BBLG.

What other companies compete with Bone Biologics?

Other companies that are similar to Bone Biologics include Micron Solutions, Helius Medical Technologies, WOWI, Intellipharmaceutics International and Motus GI. Learn More about companies similar to Bone Biologics.

How do I contact Bone Biologics' investor relations team?

The company's listed phone number is 781-552-4452 and its investor relations email address is [email protected]. The official website for Bone Biologics is www.bonebiologics.com. Learn More about contacing Bone Biologics investor relations.